Features of liver ultrastructure of rat exposed by antiretroviral drug tenofovir disoproxil fumarate in combination with S-adenosylmethionine-Reference-Cited by-同舟云学术

Features of liver ultrastructure of rat exposed by antiretroviral drug tenofovir disoproxil fumarate in combination with S-adenosylmethionine

Published:2020-03-18 Issue:1 Volume:17 Page:55-63
ISSN:2524-2350
Container-title:Proceedings of the National Academy of Sciences of Belarus, Medical series
language:
Short-container-title:Vescì Nac. akad. navuk Belarusì, Ser. med. navuk

Author:

Astrowskaja A. B.¹,Krauchuk R. I.¹,Kurbat M. M.¹

Affiliation:

1. Grodna State Medical University

Abstract

Ultrastructural changes in the liver of rats after 7and 21-days intragastric administration of tenofovir disoproxil fumarate (TDF) at a dose of 50 mg/kg/daily and correction of the revealed violations by S-adenosylmethionine (SAM) were described. Exposure of TDF for 7 days causes mild dystrophic changes in a small proportion of hepatocytes. The 21-day effect of TDF in the hepatocytes of the periportal zones shows the development of moderately pronounced dystrophy with a decrease in protein-synthetic function and slight changes in the structure of mitochondria. At both periods of administration, TDF leads to the death of single cells of the liver parenchyma and reactive intralobular inflammatory infiltration. The use of SAM on long-term administration of TDF does not reduce the intensity of core liver infiltration, but prevents the development of dystrophy of peripоrtal hepatocytes and normalizes the amount of lipid inclusions in parenchymal cells of the organ.

Publisher

Publishing House Belorusskaya Nauka

Subject

General Medicine

Reference21 articles.

1. Gallant J. E., Deresinski S. Tenofovir disoproxil fumarate. Clinical Infectious Diseases, 2003, vol. 37, no. 7, pp. 944– 950. https://doi.org/10.1086/378068

2. Fung H. B., Stone E. A., Piacenti F. J. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clinical Therapeutics, 2002, vol. 24, no. 10, pp. 1515–1548. https://doi.org/10.1016/s01492918(02)80058-3

3. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. June 2016, Geneva, Switzerland. Available at: https://www.who.int/hiv/pub/arv/arv-2016/en/ (accessed 31 May 2019).

4. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV. December 2018, Geneva, Switzerland. Available at: https://www.who.int/hiv/pub/guidelines/ARV2018update/en/ (accessed 31 May 2019).

5. Ribera E., Paradiñeiro J. C., Curran A., Sauleda S., García-Arumí E., Castella E. [et al.]. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clinical Trials, 2008, vol. 9, no. 6, pp. 407–417. https://doi.org/10.1310/hct0906-407